Bio-Techne's Q3 2026 Earnings Put Profitability Back in Focus

Bio-Techne (TECH) has just posted Q3 2026 results with revenue of US$311.4 million and basic EPS of US$0.33, setting a clear marker for how profitability is tracking this year. The company has seen quarterly revenue move from US$297.0 million in Q2 2025 to US$311.4 million in Q3 2026, while basic EPS shifted from US$0.22 to US$0.33 over the same period. This frames a recovery from the prior loss-making quarter in 2025. For investors, the latest numbers put the spotlight firmly on how margins are holding up and what that may mean for the path ahead.

See our full analysis for Bio-Techne.

With the headline figures on the table, the next step is to set these results against the most widely held narratives around Bio-Techne, to see which stories the numbers support and which they start to challenge.

Margins Sit At 9% After One-Off Hit

• On a trailing 12 month basis, Bio-Techne generated US$1.21b in revenue and US$109.5 million in net income, which works out to a 9% net margin compared with 10.9% a year earlier and includes a US$164.1 million one off loss in that period.
• Consensus narrative expects margin expansion over time, yet the current 9% margin and the five year earnings decline of about 14.4% per year highlight that recent profitability is still catching up to those expectations.
  • Analysts are looking for earnings to grow around 23.3% per year with revenue growth of roughly 7% per year, so the lower trailing margin plus the large one off loss give you a more conservative starting point than the forward view implies.
  • For a beginner investor, it is worth separating ongoing operations, reflected in the 9% margin, from the US$164.1 million one off loss when comparing the current situation with the more optimistic long term profit assumptions.

Valuation: 67.7x P/E Versus 44.4% DCF Gap

• At a share price of US$47.41, Bio-Techne trades on a 67.7x trailing P/E, which is higher than the Global Life Sciences industry average of 37.3x and a peer average of 30x, while sitting about 44.4% below a DCF fair value of US$85.23.
• Bulls point to upside, with a commonly cited analyst price target of US$70.09 and DCF fair value of US$85.23, but the premium 67.7x P/E compared with industry and peers means the optimistic view is asking you to pay more for each dollar of current earnings.
  • The difference between the current price of US$47.41 and the US$70.09 target suggests room for gains if the bullish earnings and margin forecasts play out as expected.
  • At the same time, the 67.7x P/E being above the 37.3x industry and 30x peer averages makes it important to check whether the forecast earnings growth of roughly 23.3% per year justifies paying that higher multiple today.

On these numbers, bulls are effectively arguing that today’s 67.7x P/E and 44.4% DCF gap are justified by the earnings growth they see ahead. If you want to see how that bullish case is built line by line, check out the 🐂 Bio-Techne Bull Case

Quarterly Profit Rebuilds After Prior Loss

• Looking at recent quarters, net income moved from a loss of US$17.7 million in Q4 2025 to US$38.2 million in Q1 2026, US$38.0 million in Q2 2026 and US$51.0 million in Q3 2026, while basic EPS over the same stretch went from a loss of US$0.11 to positive readings of about US$0.25, US$0.24 and US$0.33.
• Bears worry that tighter healthcare and research budgets and competition could pressure this recovery, and the five year earnings decline of about 14.4% per year together with the margin slip from 10.9% to 9% give that cautious view some grounding even as recent quarters return to profit.
  • The step from the Q4 2025 loss to three consecutive profitable quarters shows the business can generate earnings, but the lower trailing margin means bears can still point to pressure on profitability versus the prior year.
  • For you as an investor, the key tension is that quarterly profits are back in positive territory while longer term metrics still reflect that five year earnings decline, which is exactly what the more cautious narrative focuses on.

If you want to see how skeptics connect this recent profit rebuild with concerns about funding, pricing and competition, it is worth reading through the 🐻 Bio-Techne Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Bio-Techne on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With bulls and bears both finding support in the latest numbers, it makes sense to look at the underlying data yourself and move quickly to test your own thesis against the company's 3 key rewards and 1 important warning sign in 3 key rewards and 1 important warning sign.

See What Else Is Out There

Bio-Techne's five year earnings decline, slimmer 9% margin and premium 67.7x P/E all point to pressure on profitability relative to expectations.

If you want stocks where the price tag may better reflect current earnings power and balance sheet strength, it is worth checking the 45 high quality undervalued stocks today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.